Exacis Biotherapeutics Makes Strategic Investment In Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience

July 1, 2021

  • Bryan Jones PhD brings significant experience to role of Head of Technical Operations
  • Cleanroom facility gives Exacis capacity to produce mRNA-based cell therapies
  • Bypasses traditional timelines and costs associated with third-party GMP manufacturing
  • Includes iPSC derived, engineered T and NK cells

CAMBRIDGE, Mass., July 1, 2021 /PRNewswire/ — Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced two significant advances in its manufacturing capabilities. Exacis is partnering with parent Factor Bioscience to produce its iPSC-derived CAR-T and NK cells within a GMP cleanroom facility built by Factor, and Exacis has hired Bryan Jones PhD as its Head of Technical Operations.

Exacis’ parent company, Factor Bioscience, recently completed construction of a 5,000 square foot GMP cleanroom facility at its Cambridge, Massachusetts headquarters. The facility includes two ISO Class 7 cleanrooms and is designed to enable production of advanced mRNA, gene-editing, and cell therapy products to support all phases of clinical development. Exacis will use this new facility to produce its allogeneic mRNA engineered cell-therapy product candidates for non-clinical and clinical testing.